Nippon Boehringer Ingelheim Applies For Approval Of Pramipexole Suspended Release Tablet
This article was originally published in PharmAsia News
Nippon Boehringer Ingelheim submitted an approval application July 1 for Parkinson's disease drug Bi-Sifrol (pramipexole) suspended release tablet. The tablets reduce three times daily dosage to once daily and thus lessen patient burden. Pramipexole was approved for Parkinson's disease in Japan in 2003. (Click here for more - Japanese language
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.